Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

RedHill Biopharma (RDHL) Other Gross PP&E Adjustments (2019 - 2025)

RedHill Biopharma has reported Other Gross PP&E Adjustments over the past 7 years, most recently at -$1.1 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments fell 250.0% to -$1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, down 250.0% year-over-year, with the annual reading at -$1.1 million for FY2025, 250.0% down from the prior year.
  • Other Gross PP&E Adjustments was -$1.1 million for Q4 2025 at RedHill Biopharma, down from -$163000.0 in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at -$163000.0 in Q2 2025 and troughed at -$7.7 million in Q1 2022.
  • The 5-year median for Other Gross PP&E Adjustments is -$4.2 million (2021), against an average of -$3.7 million.
  • Year-over-year, Other Gross PP&E Adjustments soared 85.22% in 2023 and then tumbled 250.0% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$3.7 million in 2021, then crashed by 83.29% to -$6.7 million in 2022, then soared by 85.22% to -$989000.0 in 2023, then soared by 69.46% to -$302000.0 in 2024, then tumbled by 250.0% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Other Gross PP&E Adjustments are -$1.1 million (Q4 2025), -$163000.0 (Q2 2025), and -$302000.0 (Q4 2024).